

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2024 (15.08.2024)



(10) International Publication Number
WO 2024/165045 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *C07D 207/36* (2006.01)
(21) International Application Number:
PCT/CN2024/076657
(22) International Filing Date:
07 February 2024 (07.02.2024)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
PCT/CN2023/075152
09 February 2023 (09.02.2023) CN

(71) Applicant: **BEIGENE, LTD.**; C/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, KY1-1108 (KY).

(72) Inventor; and

(71) Applicant (for SC only): **TSAI, Charn-Sheng** [CN/CN]; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(72) Inventors: **TSAI, Mei-Hsuan**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **WEI, Xiaodong**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **LUO, Wei**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN). **WU, Liming**; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38, LinFengErLu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SELF-STABILIZING LINKER CONJUGATES



(57) Abstract: The present disclosure provides antibody drug conjugate platforms comprising a self-stabilizing linker assembly component, and antibody drug conjugates comprising platform-derived linker-payloads and antibodies or antigen-binding fragments thereof. In some embodiments, an antibody drug conjugate is of the following formula (I): or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein values for the variables (e.g., BA, RG, R^{1a}, R^{1b}, r, RS, R^{2a}, R^{2b}, s, R⁴, R^{3a}, R^{3b}, t, RE, A, a', W, w', Y, y', PA, x) are as described herein.

WO 2024/165045 A1